RoosterBio and Qkine Join Forces to Create Comprehensive Cell Therapy Solutions for U.S. Market

Introduction to the Partnership

In a strategic move poised to reshape the landscape of cellular therapy, RoosterBio, Inc. has announced a partnership with Qkine Ltd. This collaboration aims to provide U.S. customers unparalleled access to a comprehensive range of high-quality cells, bioprocess media, and recombinant growth factors, all sourced from a unified vendor. As the demand for advanced therapies continues to rise, this partnership is set to become an essential resource for developers involved in cell and exosome therapy.

Details of the Distribution Agreement

Under this distribution agreement, RoosterBio will offer Qkine's full portfolio of translation-friendly research-use-only (RUO) growth factors and cytokines. This is particularly beneficial for researchers and developers engaged in advanced therapeutic applications, as it eliminates the complexity typically associated with sourcing multiple vendors. By providing a single source for critical raw materials, this partnership simplifies the supply chain for U.S.-based developers and researchers, enabling them to focus on their core mission: innovation in cell therapy.

Benefits for U.S. Developers

One of the standout features of this partnership is that it will streamline access for developers in the United States. High-quality ancillary materials are necessary for effective process development, and RoosterBio's establishment as a domestic supplier addresses the urgent need for fast and reliable sourcing. This efficiency is vital for developers aiming to translate their research into commercially viable therapies rapidly.

RoosterBio offers a unique range of cellular products, engineered bioprocess media, and exosome production solutions designed to optimize manufacturing workflows. The integration of Qkine's recombinant proteins is a significant enhancement to this offering, ensuring that developers have access to the purity and consistency required for demanding cell and exosome workflows.

Commitment to Quality and Translation-Readiness

Both RoosterBio and Qkine share a commitment to translation-readiness; their products are manufactured in a manner that ensures the RUO versions utilized in research align seamlessly with corresponding GMP-grade products. This alignment allows for a seamless transition to large-scale GMP manufacturing, which is critical for advancing therapy products to clinical trials and eventual commercial use.

Tim Kelly, CEO of RoosterBio, emphasized that incorporating high-quality recombinant growth factors and cytokines is essential for the efficacy and cost efficiency of advanced therapy products. This partnership will not only enhance RoosterBio's technology platform but will also ensure that they continue to meet the ever-evolving needs of their clients.

Qkine's Contribution to the Collaboration

Qkine, based in Cambridge, UK, is renowned for its production of high-purity and animal origin-free growth factors and cytokines. Their proprietary recombinant production processes coupled with advanced protein engineering techniques result in proteins that support various applications in life sciences, particularly in the realms of cell and gene therapy. As Rob Scoffin, Interim CEO of Qkine, states, this partnership with RoosterBio significantly expands their reach within the critical U.S. market, aligning them with key researchers and developers who are at the forefront of revolutionizing cell and gene therapy.

Conclusion and Future Outlook

With the strategic partnership between RoosterBio and Qkine, U.S. developers of cell and gene therapies can look forward to a more efficient and reliable sourcing of the critical materials needed for innovation. As both companies collaborate, they will leverage their respective strengths to build out joint capabilities, addressing pressing needs within the industry. This partnership not only signifies a significant step towards simplifying the supply chain for therapeutic development but also underscores the importance of maintaining high standards of quality and reliability within the fast-evolving field of advanced therapies.

For further information on RoosterBio’s offerings and to explore the full range of Qkine’s products, visit RoosterBio's website.